Despite Media Report, Alex Azar Likely To Stay At HHS
Executive Summary
AdvaMed CEO Scott Whitaker, a close friend and confidant of US HHS Secretary Alex Azar, says despite some reports that Azar is being eyed to replace US Attorney General Jeff Sessions, he is very likely staying at the department. Whitaker says that's a good thing for the medtech industry.
You may also be interested in...
AdvaMed CEO: Less Optimistic On Full Device Tax Repeal By Deadline
In an exclusive sit-down with Scott Whitaker, the head of the largest medical device lobby group tells Medtech Insight why pharmaceutical companies should be concerned about Trump HHS Secretary nominee Alex Azar, his frustration with Congress' device tax repeal efforts, the growing likelihood of another temporary device tax moratorium and more. Listen to the podcast.
Massive Family Dollar Rat Infestation Leads To Multi-State Recall
The US FDA found more than 2,000 rats at an Arkansas Family Dollar distribution center, leadingto a six-state recall for products including feminine hygiene products, contact lens cleaners and face masks.
Digital Health Roundup: Exec Chats With Illumina, Bloom, AngelMed; M&A, Funding; FDA Down-Classifies Apps
In this roundup feature focusing on new developments in digital health, Medtech Insight spotlights IBM Watson Health’s divestiture and other financing news, Exec Chats with Illumina, AngelMed and Bloom, Philips’ new hand-held ultrasound device and autonomous robotic surgery, as well as the latest FDA news on digital health.